Selvax Cancer Immunotherapy | Perth, Western Australia
5
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.2,wpb-js-composer js-comp-ver-5.3,vc_responsive

Selvax Pty Ltd, a West Australian based cancer immunology group is developing a novel immunology based treatment for large solid tumours

 

Led by Curtin University immunologist Assoc Prof Delia Nelson, the team has made encouraging progress in the treatment of large solid tumours in animals by administration of selected immunological agents into the tumour micro environment. The technology has achieved cancer clearance rates in the range of 60% – 80% in repeated small animal studies for a range of solid tumours and has shown the capacity to protect against recurrence of the cancer.

 

SUPPORTED BY:

Curtin Partners with Selvax to Develop Cancer Treatments